Schering Corporation

Merck Sharp + Dohme Corp.

Schering-Plough Corporation

Paul Reichert

Tattanahalli L. Nagabhushan

Hung V. Le

Gerald S. Hammond

Paul P. Trotta

Vincent Stewart Madison

Alan W Hruza

Shahriar Shane Taremi

Tattanahalli L Nagabhushan

Hung V Le

Paul P Trotta

Corey Strickland

Thomas E Hesson

Thierry Olivier Fischmann

William T Windsor

Winifred W Prosise

Gerald S Hammond

Peter Orth

Patricia C Weber

Yaolin Wang

Rumin Zhang

Jose S Duca

Andrew Joseph Prongay

Li Xiao

Wenyan Wang

Charles W McNemar

Todd W Mayhood

Anthony F Mannarino

Catherine Smith

Ashit K Ganguly

Gerald Wayne Shipps, Jr

Charles A Lesburg

Brian M Beyer

Richard N Ingram

Wolfgang Seghezzi

Stephen Tindall

Nanhua Hugh Yao

Yao Ma

Ramesh Kashi

Gail F Seelig

Lata Ramanathan

Jessie M English

Thierry Oliver Fischmann

Kuo-Chi Cheng

Weihong Jin

David Paul Sanden

Gaolian Xie

Rosalinda Syto

Joseph E Myers

Chandra C Kumar

Tin-Yau Chan

Nicholas J Murgolo

Nagamani Nagabhushan

Henry R Sochon

Eric William Kaler

Jun Zou

Chakravarthy Nachu Narasimhan

Giovanna Scapin

Robert A Kosecki

Harold K Kushner

Chakravarthy Narasimhan

Jennifer Joanne Gesell

Marianna Marshall Long

Dingjiang Liu

Xiaoyu Yang

Rowena F Choudrie

Bruce O Stuart

Nagamani Nagabushan

T L Nagabhushan

Nagamani Nagahhushan

Tattanahalli L Nagahhushan

Lorraine Hernandez

Payal Sheth

Alex Therien

Daniel F Wyss

Ramesh S Kashi

Crystals of pembrolizumab and structurally similar anti-PD-1 monoclonal antibodies are provided, as well as methods of producing such crystals, and uses of compositions comprising such antibody crystals, e.g. in treatment of cancers. The present invention satisfies these needs and more by providing pembrolizumab crystals and a method producing pembrolizumab crystals. One embodiment of the method of the invention produces crystals suitable for X-ray diffraction, and the inventors herein used such crystals to solve the three-dimensional structure of pembrolizumab to 2.3 A resolution.

Crystals of anti-human PD-1 monoclonal antibodies

Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19 , are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e. they maintain biological activity of the anti-huiL-23 antibody, such as anti-huiL-23p 19 antibody, longer than corresponding solution formulations.

Crystalline anti-human IL-23p19 antibodies

The present invention provides polypeptide domains oftoxin B (B1, B2, B3, B4) and complexes between the polypeptides and antibodies that bind specifically for the polypeptide. Methods of using the polypeptides to generate antibodies are also provided.

C.difficile toxin B CROP domain peptides, antibodies and complexes thereof

The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.

Factor IXa crystals, related complexes and methods

This application covers a novel PEGylated interferon and a novel crystalline form of interferon which are useful, inter alia, for detailed structural analysis of interferon as well as treatment and prevention of viral infections and hyperproliferative diseases such as leukemia.

Crystal of human interferon alpha 2B in complex with zinc

The present invention provides, inter alia, crystals of the MEK1 polypeptide which are particularly useful for structure based drug design as well as methods of use thereof.

MEK1 polypeptides

The present invention provides, in part, AKT3 polypeptides and methods of use thereof along with nucleic acids encoding the polypeptides. For example, methods for screening for AKT3 inhibitors are provided herein.

Kinase domain polypeptide of human protein kinase B gamma (AKT3)

The present invention relates to Pregnane X receptor (PXR) polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.

Crystal of pregnane X receptor fused to steroid receptor coactivator-1

The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.

Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides

The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.

HDM2 polypeptides

The present invention discloses nucleic acids that encode an active human Aurora 2 kinase catalytic domain. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human Aurora 2 kinase catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human Aurora 2 kinase. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human Aurora 2 kinase in structure assisted drug design to identify compounds that can modulate the enzymatic activity of human Aurora 2 kinase.

Method for crystallizing aurora 2 kinase catalytic domain polypeptide

The present invention relates, inter alia, to PXR polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.

Pregnane X receptor compositions, crystals and uses thereof

Polynucleotides encoding polypeptide fragments of protein kinase B gamma (AKT3)

The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.

Methods for crystallizing ERK2 polypeptides

Growing community of inventors

Montville, NJ, United States of America

Paul Reichert